BMS
Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
ArcherDx, Bristol Myers Squibb Partner on Minimal Residual Disease Monitoring
ArcherDX said the firms aim to apply minimal residual disease monitoring in clinical-trial protocols and for future therapy optimization.
Agilent PD-L1 Assay Gets FDA Approval as Metastatic NSCLC Companion Diagnostic
Clinicians will be able to use the assay to help identify patients with metastatic NSCLC for treatment with nivolumab and ipilimumab.Â
Feb 28, 2018